Alzamend Neuro (NASDAQ:ALZN) Releases Quarterly Earnings Results, Misses Estimates By $0.07 EPS

Alzamend Neuro (NASDAQ:ALZN) released its quarterly earnings results on Wednesday. The company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by ($0.07), Zacks reports.

Alzamend Neuro Price Performance

Alzamend Neuro stock opened at $1.26 on Friday. The stock’s 50 day moving average is $1.19 and its 200 day moving average is $1.51. Alzamend Neuro has a one year low of $0.84 and a one year high of $3.04. The firm has a market cap of $4.79 million, a P/E ratio of -0.43 and a beta of 0.14.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Alzamend Neuro stock. Geode Capital Management LLC raised its position in Alzamend Neuro, Inc. (NASDAQ:ALZN) by 33.7% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 27,506 shares of the company’s stock after purchasing an additional 6,928 shares during the period. Geode Capital Management LLC owned 0.72% of Alzamend Neuro worth $50,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 49.61% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings downgraded Alzamend Neuro from a “sell (e+)” rating to a “sell (e)” rating in a report on Monday. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Alzamend Neuro presently has an average rating of “Hold” and an average price target of $28.00.

About Alzamend Neuro

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.